首页> 外国专利> Antitumour medicaments contg. metal complexes - comprising beta-di:ketone complexes of tin, titanium, zirconium or hafnium

Antitumour medicaments contg. metal complexes - comprising beta-di:ketone complexes of tin, titanium, zirconium or hafnium

机译:抗肿瘤药物续。金属配合物-包含锡,钛,锆或ha的β-二:酮配合物

摘要

Medicaments contg. complexes of formula (R1(CH2)mCOCR3COR2)xM(X)y (I) are new. M is Sn, Ti, Zr or Hf; R1 is H or phenyl opt. mono- or polysubstd. by F, Cl, Br, NO2, 1-4C alkyl, 1-4C alkoxy or CF3; R2 is Me or R1, but not H; R3 is H or Cl; X is F, Cl or Br, but not F when M is Zr or Hf; m is 1 or 0 but must be 1 when R1 is H; x= 2+n; y= 2-n; n is 0 or can also be 1 when M is Zr or Hf. Cpds. (I) are new, provided that (i) R1 is not H, (ii) R1 is not Ph when M is Sn or Ti; although R2 can be Ph for any M, (iii) X is not Cl when M is Zr and R1 is Ph, (iv) X is not Cl when M is Hf, R1 is Ph and n= 1, and (v) X is not Cl when M is Ti and R1 is p-fluoro-, p-chloro- or p-bromophenyl. Coprecipitates of (I) with hydrophilic polymers are also new. (I) are antitumour agents with comparable cytostatic activity to cis-Pt(NH3)2Cl2 but much lower toxicity.
机译:药品续式(R1(CH2)mCOCR3COR2)xM(X)y(I)的配合物是新的。 M为锡,钛,锆或H。 R1是H或苯基。单或多取代。由F,Cl,Br,NO 2,1-4C烷基,1-4C烷氧基或CF 3; R2是Me或R1,但不是H; R3为H或Cl; X是F,Cl或Br,但当M是Zr或Hf时不是F; m为1或0,但当R1为H时必须为1; x = 2 + n; y = 2-n;当M为Zr或Hf时,n为0或也可以为1。 Cpds。 (I)是新的,只要(i)R1不是H,(ii)当M是Sn或Ti时R1不是Ph;尽管R2对于任何M均可为Ph,(iii)当M为Zr并且R1为Ph时X不为Cl,(iv)当M为Hf时R1为Ph且n = 1时X不为Cl,(v)X当M为Ti且R1为对氟,对氯或对溴苯基时,Cl不为Cl。 (I)与亲水性聚合物的共沉淀物也是新的。 (I)是具有与顺式Pt(NH3)2Cl2相当的细胞抑制活性,但毒性要低得多的抗肿瘤剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号